-+ 0.00%
-+ 0.00%
-+ 0.00%

Ensysce Biosciences Outlines Plans to Sequence PF614-301 Phase 3 Timeline, Reduce Regulatory Uncertainty, Prioritize PF614 and Related Pipeline Programs, and Evaluate PF614 Commercial Opportunities

Reuters·03/04/2026 13:45:19

Please log in to view news